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Dr Keith Horvath (Bethesda, Md). Thank you, Dr Kelly,
excellent presentation of some very intriguing work. I have just
a few questions.The Journal of Thoracic and CaThe results that you show document that there is some persistent
dysfunction particularly at the mitochondrial level after revascu-
larization. Are you convinced that this is because of that at the cel-
lular level or is it possible that there still is a blood flow problem?
You’ve documented that the baseline resting blood flow returns to
normal but with dobutamine stress there is a difference. Again, is it
a result of the flow in or is it as a result of the mitochondrial dys-
function?
From a mechanistic point of view, what do you postulate is
causing this? One of the main reasons may be apoptosis, and do
you have any data that supports that as the principal mechanism?
And then, finally, from a clinical implication point of view, is
there something that we should be doing in the operating room
or postoperatively to prevent this from happening? And then to
delve somewhat into a controversial area, is this because these
were performed off-pump instead of on-pump?
Dr Kelly. Thank you for your questions.
To begin with, we did consider other reasons for decreased per-
fusion. We looked at the vascular reactivity in the resistant vessels
of the myocardium and what we found is that the contractility re-
mained normal in the LAD versus circumflex vessels. What we
have not yet investigated, and our future studies are designed to
study, is the ability of the LAD vessels to relax normally. I think
when we perform a dobutamine stress test, what may be happening
is a signaling for dilation towhich thevasculature in the hibernating
tissue is unable to respond. That will be for future considerations.
When we looked at possible mechanisms as to why the myocar-
dial function remains abnormal, we did not look specifically for
apoptosis within the tissue. But looking at the histology and the
electron microscopy, we have found that these cells and mitochon-
drial remain normal in appearance and have not noticed a signifi-
cant presence of necrosis or fibrosis.
As the cellular and tissue structure remained intact following
chronic ischemia and revascularization, we investigated other pos-
sible mechanisms by which the cells fail to recover upon revascu-
larization and focused on oxygen utilization in the mitochondria.
With uncoupling of oxidative phosphorylation, the mitochondria
are unable to maximally respond to the oxygen delivered and
ATP production remains impaired. When we looked at the mito-
chondrial function using Clark’s electrode, the respiratory control
index in hibernating tissue remained depressed. When we looked
at our revascularized hibernating tissue compared to remote, it re-
mained depressed as well. This finding suggests that the mitochon-
dria themselves remain dysfunctional compared to normal tissue.
And finally, I agree with you, the off-pump technique could
clearly impact the microthrombus occurring in these animal
models. In particular for this model, pigs can be very thrombo-
genic. However, for technical support and recovery reasons, it
was better to do the procedure off-pump and we did not see any
evidence of thrombus intraoperatively or evidence of infarction
at the time of the terminal study. Also, we aggressively heparinized
the animals to prevent thrombosis
Dr Paul Kurlansky (Miami, Fla). Beautiful piece of work, it
was very intriguing. I had 3 questions.
One was, clearly you seem to be postulating that there is some
sort of trigger which is set off in the hibernatingmyocardiumwhich
is not readily reversed. Do you have any idea specifically what this
trigger is mechanistically and how we therefore might address it?rdiovascular Surgery c Volume 141, Number 1 267




SSecondly, another approach might be whether or not you had
looked at the effect of a preconditioning, preconditioner, even
postconditioning, and if it somehow affects the ability of revascu-
larization to turn this trigger the other direction.
And the third question is, it’s very difficult to do the experiments
you’re doing and it’s even more difficult to do them for prolonged
survival; however, over time, do you have any idea if after several
months does the trigger get reversed with adequate revasculariza-
tion?
Dr Kelly.We don’t know what the trigger for hibernation is but
agree that there is some alteration that occurs in the mitochondria
that moves it into survival mode rather than necrosis or apoptosis.
It is possibly an upregulation of uncoupling protein but the trigger
for this response is unclear. Discovering that trigger, and the mech-
anism for reversal, is an important part of our investigations going
forward.268 The Journal of Thoracic and Cardiovascular SurgWehave looked at the spectrum of preconditioning in relation to
hibernation, but not yet in the revascularization model. However, if
you look at what we’ve created, we seem to have transitioned from
hibernation to stunned myocardium, where you have normal blood
flow yet depressed function. If we continue on that spectrum, we
may indeed see that finally at a year the myocardial function would
return to normal.
We plan to allow for more prolonged recovery in this animal
model to study the recovery of the myocardium over time. This
will mimic the clinical experience of continued recovery over sev-
eral months. For me, as a clinician, the question would be: How
can I help that recovery occur more quickly following revascular-
ization? We are looking at manipulating possible triggers using
pharmacologic adjuvant therapy as well as using stem cells to per-
mit more rapid recovery. Those are our speculations for the future
directions using this model.ery c January 2011
